Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts
US10519121B2 · kind B2 · utility
0Cited by
27References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 26, 2017 |
| Grant date | Dec 31, 2019 |
| Priority date | — |
| Expiry date | Dec 26, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/13
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Processes are disclosed for making vortioxetine and pharmaceutically acceptable salts thereof. A propylene glycol solvate of vortioxetine hydrobromide is disclosed. A novel crystalline form of vortioxetine hydrobromide propylene glycol solvate, designated form AC1, is disclosed along with a method for making same. Form AC1 may be characterized by an x-ray powder diffraction pattern with peaks at about 19.64, 22.85, 25.51, 29.57, 30.18±0.2 degrees 2-theta.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.